BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2561834)

  • 1. A new analysis of whole-body calorimetry data.
    Lynch TJ; Martinez RP; Furman MB; Geller EB; Adler MW
    NIDA Res Monogr; 1989; 95():289-90. PubMed ID: 2561834
    [No Abstract]   [Full Text] [Related]  

  • 2. Kappa antagonist effects of buprenorphine in the rat drug-discrimination procedure.
    Negus SS; Picker MJ; Dykstra LA
    NIDA Res Monogr; 1989; 95():518-9. PubMed ID: 2561845
    [No Abstract]   [Full Text] [Related]  

  • 3. Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action.
    Millan MJ; Członkowski A; Lipkowski A; Herz A
    J Pharmacol Exp Ther; 1989 Oct; 251(1):342-50. PubMed ID: 2571723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of morphine tolerance-dependence and abstinence on kappa-opiate receptors of rat brain and spinal cord.
    Bhargava HN; Gulati A; Rahmani NH
    Biochem Pharmacol; 1991 Aug; 42(6):1302-6. PubMed ID: 1653568
    [No Abstract]   [Full Text] [Related]  

  • 5. Selective kappa opioid agonist for spinal analgesia without the risk of respiratory depression.
    Castillo R; Kissin I; Bradley EL
    Anesth Analg; 1986 Apr; 65(4):350-4. PubMed ID: 3006552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist.
    Vonvoigtlander PF; Lahti RA; Ludens JH
    J Pharmacol Exp Ther; 1983 Jan; 224(1):7-12. PubMed ID: 6129321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similar actions of kappa and mu agonists on spinal nociceptive reflexes in rats and their reversibility by naloxone.
    Parsons CG; West DC; Headley PM
    NIDA Res Monogr; 1986; 75():461-4. PubMed ID: 2828992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of kappa opioid receptors by U50488H and morphine enhances the release of substance P from rat trigeminal nucleus slices.
    Suarez-Roca H; Maixner W
    J Pharmacol Exp Ther; 1993 Feb; 264(2):648-53. PubMed ID: 7679733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential activity of selective opioid agonists on hypothalamic magnocellular neuronal activity.
    Clarke G; Davison I; MacMillan SJ; Wright DM
    Prog Clin Biol Res; 1990; 328():351-4. PubMed ID: 2154792
    [No Abstract]   [Full Text] [Related]  

  • 10. The effect of mu and kappa opioid receptor agonists on cAMP level in hippocampus of kainic acid-treated rats.
    Dziedzicka-Wasylewska M; Przewłocki R
    Pol J Pharmacol; 1995; 47(2):121-6. PubMed ID: 8688884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of a mu- and kappa-opioid agonist on isoflurane minimal anesthetic concentration in chickens.
    Concannon KT; Dodam JR; Hellyer PW
    Am J Vet Res; 1995 Jun; 56(6):806-11. PubMed ID: 7653892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mu antagonist properties of kappa agonists in a model of rat urinary bladder motility in vivo.
    Sheldon RJ; Nunan L; Porreca F
    J Pharmacol Exp Ther; 1987 Oct; 243(1):234-40. PubMed ID: 2822899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrophysiological demonstration of mu, delta and kappa opioid receptors in the ventral pallidum.
    Mitrovic I; Napier TC
    J Pharmacol Exp Ther; 1995 Mar; 272(3):1260-70. PubMed ID: 7891342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Synthesis and analgesic activity of 3,4-dichloro-N-methyl-N-[trans-2-(1-delta 3-pyrrolinyl)-cyclohexyl]-benzenacetamide hydrochloride].
    Ma SC; Lu SN; Li KZ; Wang CQ
    Yao Xue Xue Bao; 1986 Nov; 21(11):861-3. PubMed ID: 3035865
    [No Abstract]   [Full Text] [Related]  

  • 15. Peptide opioid antagonist separates peripheral and central opioid antitransit effects.
    Shook JE; Pelton JT; Hruby VJ; Burks TF
    J Pharmacol Exp Ther; 1987 Nov; 243(2):492-500. PubMed ID: 2824748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonist-induced opioid receptor up-regulation. I. Characterization of supersensitivity to selective mu and kappa agonists.
    Millan MJ; Morris BJ; Herz A
    J Pharmacol Exp Ther; 1988 Nov; 247(2):721-8. PubMed ID: 2846827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Respiratory effects of receptor-selective opioids in rhesus monkeys.
    France CP; Woods JH
    Prog Clin Biol Res; 1990; 328():295-8. PubMed ID: 2154784
    [No Abstract]   [Full Text] [Related]  

  • 18. Identification of a novel class of highly potent sigma ligands related to the kappa-selective agonist U50,488.
    Radesca LA; deCosta BR; Bowen WD; DiPaolo LJ; Rice KC
    NIDA Res Monogr; 1990; 105():518-9. PubMed ID: 1652089
    [No Abstract]   [Full Text] [Related]  

  • 19. Chronic naloxone treatment induces supersensitivity to a mu but not to a kappa agonist at the hypothalamus-pituitary-adrenocortical axis level.
    Alcaraz C; Vargas ML; Fuente T; Milanés MV
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1602-6. PubMed ID: 8396640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Central depressor effect of U50488H: a highly selective kappa opioid agonist].
    Feng Y; Han JS
    Sheng Li Xue Bao; 1987 Jun; 39(3):305-9. PubMed ID: 2823391
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.